Ginah Nightingale, PharmD, BCOP, of Thomas Jefferson University, Philadelphia, PA, discusses why cognitive impairment as a result of chemotherapy is not screened for, as well as how this should be tested and its importance. This video was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.
Screening for cognitive impairment in patients receiving chemotherapy
